Fushine Pharmaceutical Outlines Strategy to Strengthen Core API Business and Expand into New Growth Areas

Deep News06-14

In response to inquiries from analysts, Jiangxi Fushine Pharmaceutical Co.,Ltd. has detailed its forward-looking strategic plan.

The company's pharmaceutical manufacturing operations will serve as its foundational business, concentrating on high-value-added active pharmaceutical ingredients (APIs). The strategy involves deepening its expertise, solidifying, and expanding its dominant position within its established pharmaceutical sectors.

Concurrently, its new energy lithium battery electrolyte additives business aims to establish a comprehensive one-stop raw material supply platform. This initiative is designed to offer customers a broader product portfolio and more reliable supply chain security.

For its bio-manufactured microbial protein segment, the company will adopt a dual-engine approach targeting both business and consumer markets. On the business-to-business (B2B) front, it will supply microbial protein raw materials and integrated food solutions to downstream food enterprises. For the consumer (B2C) market, expansion will be pursued through its proprietary brands and co-branding partnerships.

By fostering the synergistic development of these three core business areas, the company is committed to evolving into a leading enterprise dedicated to safeguarding both the global environment and human health.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181176877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-14 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181176877","market":"other","top_or_hot":-1,"title":"Fushine Pharmaceutical Outlines Strategy to Strengthen Core API Business and Expand into New Growth Areas","media":"Deep News","content":"<p>In response to inquiries from analysts, <b>Jiangxi Fushine Pharmaceutical Co.,Ltd.</b> has detailed its forward-looking strategic plan.<br><br>The company's pharmaceutical manufacturing operations will serve as its foundational business, concentrating on high-value-added active pharmaceutical ingredients (APIs). The strategy involves deepening its expertise, solidifying, and expanding its dominant position within its established pharmaceutical sectors.<br><br>Concurrently, its new energy lithium battery electrolyte additives business aims to establish a comprehensive one-stop raw material supply platform. This initiative is designed to offer customers a broader product portfolio and more reliable supply chain security.<br><br>For its bio-manufactured microbial protein segment, the company will adopt a dual-engine approach targeting both business and consumer markets. On the business-to-business (B2B) front, it will supply microbial protein raw materials and integrated food solutions to downstream food enterprises. For the consumer (B2C) market, expansion will be pursued through its proprietary brands and co-branding partnerships.<br><br>By fostering the synergistic development of these three core business areas, the company is committed to evolving into a leading enterprise dedicated to safeguarding both the global environment and human health.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fushine Pharmaceutical Outlines Strategy to Strengthen Core API Business and Expand into New Growth Areas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFushine Pharmaceutical Outlines Strategy to Strengthen Core API Business and Expand into New Growth Areas\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-06-14 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>In response to inquiries from analysts, <b>Jiangxi Fushine Pharmaceutical Co.,Ltd.</b> has detailed its forward-looking strategic plan.<br><br>The company's pharmaceutical manufacturing operations will serve as its foundational business, concentrating on high-value-added active pharmaceutical ingredients (APIs). The strategy involves deepening its expertise, solidifying, and expanding its dominant position within its established pharmaceutical sectors.<br><br>Concurrently, its new energy lithium battery electrolyte additives business aims to establish a comprehensive one-stop raw material supply platform. This initiative is designed to offer customers a broader product portfolio and more reliable supply chain security.<br><br>For its bio-manufactured microbial protein segment, the company will adopt a dual-engine approach targeting both business and consumer markets. On the business-to-business (B2B) front, it will supply microbial protein raw materials and integrated food solutions to downstream food enterprises. For the consumer (B2C) market, expansion will be pursued through its proprietary brands and co-branding partnerships.<br><br>By fostering the synergistic development of these three core business areas, the company is committed to evolving into a leading enterprise dedicated to safeguarding both the global environment and human health.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1181176877","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181176877","pubTimestamp":1781445645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"In response to inquiries from analysts, Jiangxi Fushine Pharmaceutical Co.,Ltd. has detailed its forward-looking strategic plan.The company's pharmaceutical manufacturing operations will serve as its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","300497":"富祥股份","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","BK0201":"可转债"},"translate_title":"福信药业概述加强核心原料药业务并拓展新增长领域的战略","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"300497":1,"09939":1},"content_text":"In response to inquiries from analysts, Jiangxi Fushine Pharmaceutical Co.,Ltd. has detailed its forward-looking strategic plan.The company's pharmaceutical manufacturing operations will serve as its foundational business, concentrating on high-value-added active pharmaceutical ingredients (APIs). The strategy involves deepening its expertise, solidifying, and expanding its dominant position within its established pharmaceutical sectors.Concurrently, its new energy lithium battery electrolyte additives business aims to establish a comprehensive one-stop raw material supply platform. This initiative is designed to offer customers a broader product portfolio and more reliable supply chain security.For its bio-manufactured microbial protein segment, the company will adopt a dual-engine approach targeting both business and consumer markets. On the business-to-business (B2B) front, it will supply microbial protein raw materials and integrated food solutions to downstream food enterprises. For the consumer (B2C) market, expansion will be pursued through its proprietary brands and co-branding partnerships.By fostering the synergistic development of these three core business areas, the company is committed to evolving into a leading enterprise dedicated to safeguarding both the global environment and human health.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181176877","isCrawlerRequest":true}